LHX insider sold $28.28M recently; new 40,138-share sale planned for $10.82M

Rhea-AI Filing Summary

Form 144 filed for L3Harris Technologies (LHX) shows an insider notice to sell 40,138 shares on 08/11/2025 on the NYSE, with an aggregate market value of $10,818,005.61. The filing identifies the seller in recent sale history as Christopher E. Kubasik and reports that the securities to be sold were acquired under an option granted on 12/20/2017 from the issuer, with payment in cash on 08/11/2025.

The filing also discloses three sales by Christopher E. Kubasik in the prior three months totaling 107,273 shares for $28,282,910.76 (sales on 06/11/2025, 06/12/2025 and 07/29/2025). The 40,138-share notice represents approximately 0.0215% of the 187,094,798 shares outstanding reported in the form; the prior three months' sales represent approximately 0.0573% of outstanding shares. The signer certifies no undisclosed material adverse information is known.

Positive

• Transparent Rule 144 disclosure showing dates, share counts, broker and aggregate values for planned and recent sales
• Securities originated from an option granted on 12/20/2017, with the filing showing cash payment on 08/11/2025, indicating documented compensation action

Negative

• Substantial insider dispositions in dollar terms: prior three-month sales totaled $28,282,910.76
• Additional planned sale of $10,818,005.61 on 08/11/2025 by the same insider may draw investor attention despite representing small percentages of outstanding stock

Insights

Financial Analyst

TL;DR: Insider Christopher E. Kubasik plans to sell 40,138 shares ($10.82M) after selling 107,273 shares for $28.28M in the prior three months.

The filings document significant dollar-value insider sales concentrated over recent months but represent very small fractions of the issuer's reported outstanding shares: ~0.0215% for the planned sale and ~0.0573% for prior three-month sales. From a financial-analyst perspective, these transactions are material in absolute dollars yet limited in share-count relative to total equity outstanding, reducing the likelihood of direct dilution or balance-sheet impact. The use of option proceeds and cash payment is consistent with routine executive compensation exercises and dispositions disclosed under Rule 144.

Corporate Governance Expert

TL;DR: Repeated recent insider sales are notable for governance monitoring but the filings show Rule 144 compliance and explicit disclosures.

The Form 144 provides transparent disclosure of both the planned sale and recent dispositions by the same insider, including dates, amounts, and gross proceeds. The filer attests to lacking undisclosed material adverse information and documents that the securities originated from an option grant dated 12/20/2017. For governance review, the pattern of sales merits monitoring for consistency with disclosed trading plans or prearranged instructions, but the form contains no indication of noncompliance or material company-specific adverse information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	40138	10818005.61	187094798	08/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2025	Option Granted - 12/20/2017	Issuer			40138	08/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher E. Kubasik 1025 West NASA Boulevard Melbourne FL 32919	Common	06/11/2025	2212	546387.00
Christopher E. Kubasik 1025 West NASA Boulevard Melbourne FL 32919	Common	06/12/2025	33061	8214825.36
Christopher E. Kubasik 1025 West NASA Boulevard Melbourne FL 32919	Common	07/29/2025	72000	19521698.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is the filer and seller in the LHX Form 144?

The filing names Christopher E. Kubasik as the person associated with the reported sales.

How many shares are planned for sale and what is the aggregate market value?

The Form 144 notifies a planned sale of 40,138 shares with an aggregate market value of $10,818,005.61 on 08/11/2025.

What prior insider sales does the filing disclose for the last three months?

The filing lists sales on 06/11/2025 (2,212 shares, $546,387.00), 06/12/2025 (33,061 shares, $8,214,825.36), and 07/29/2025 (72,000 shares, $19,521,698.40), totaling 107,273 shares for $28,282,910.76.

How were the securities to be sold acquired?

The securities to be sold were acquired under an option granted on 12/20/2017 from the issuer; the acquisition and payment are reported as 08/11/2025 with cash payment.

What fraction of outstanding shares do these sales represent?

Based on the filing's outstanding share count of 187,094,798, the planned 40,138-share sale is ~0.0215% and the prior three-month sales (107,273 shares) are ~0.0573% of outstanding shares.